Azilva tablets 20 mg for hypertension (angiotensin receptor blocker, azilsartan, Edarby, Edarbyclor)

General information on Japanese Azilva tablets 20 mg for hypertension (angiotensin receptor blocker, azilsartan, Edarby, Edarbyclor)

Package details: 100 tablets

Manufacturer: Takeda Pharmaceutical Co., Ltd., Japan

Active ingredient: azilsartan (chemical formula C25H20N4O5)

Medical effect: Azilva tablets are effective for the treatment of hypertension.

Contraindications and precautions: do not use for the following categories of patients:

• pregnant, possibly pregnant or breastfeeding women,
• patients with high blood potassium level,
• patients with renal disorder, liver disorder or cerebrovascular disorder,
• preoperative patients,
• patients receiving hemodialysis,
• patients under low-salt diet treatment.

As this medicine may cause dizziness, be careful when working at heights, operating dangerous machinery or driving a car.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Azilva tablets 20 mg from Japan for hypertension (azilsartan, Edarby, Edarbyclor)

For adults: take 1 tablet 1 time a day. The dosage can be adjusted by the doctor in charge according to age and symptoms, but the maximum of 2 tablets (40 mg of active ingredient) once a day should not be exceeded.

How effective are Azilva tablets 20 mg from Japan for hypertension (azilsartan, Edarby, Edarbyclor)?

Azilva tablets contain azilsartan, an angiotensin II receptor antagonist. It works by blocking angiotensin receptors in smooth muscle cells of vessels. By this, Azilva tablets effectively reduce peripheral vascular resistance and lower the blood pressure.

Who should take Azilva tablets 20 mg from Japan?

Azilsartan was developed in Japan by Takeda Pharmaceutical. Recently it got approved in Europe and USA, but in a different form (azilsartan medoxomil, a prodrug), while in Japan the active metabolite form is licensed. Clinical studies enrolling more than 6000 patients proved that azilsartan provides a very potent and long-lasting hypertension treatment compared to other angiotensin II receptor blockers (H. Takagi, Y. Mizuno et al. “A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction”. Hypertension Research, 2014:37, 432–437).